Table 4.
Late sequelae by treatment group
| Late sequelae independent of recurrence timepoint | Late sequelae before recurrencea | |||||
|---|---|---|---|---|---|---|
| Late sequelae | ASCT | MT | P-valuea | ASCT | MT | P-valuea |
| Intention to treat | % of 149 | % of 146 | % of 149 | % of 146 | ||
| Auditory impairment | 25 | 20 | 0.330 | 20 | 13 | 0.118 |
| Renal impairment | 8 | 10 | 0.550 | 6 | 7 | 0.816 |
| Thyroid dysfunction | 9 | 8 | 0.440 | 8 | 8 | 1.000 |
| Focal nodular hyperplasia of the liver | 6 | 1 | 0.019 | 6 | 1 | 0.019 |
| Hepatopathy | 4 | 1 | 0.121 | 3 | 1 | 0.214 |
| Peripheral neuropathy | <1 | <1 | 1.000 | 0 | <1 | 0.244 |
| Growth retardation | 2 | 3 | 0.721 | 1 | 3 | 0.444 |
| Cardiomyopathy | 0 | 2 | 0.120 | 0 | 2 | 0.120 |
| Residual transverse myelopathy | 0 | <1 | 0.495 | 0 | <1 | 0.495 |
| Persisting thrombocytopenia | <1 | <1 | 1.000 | <1 | <1 | 1.000 |
| Visual impairment | 2 | 3 | 0.498 | 1 | 2 | 0.682 |
| As treated | % of 110 | % of 102 | % of 110 | % of 102 | ||
| Auditory impairment | 31 | 21 | 0.116 | 21 | 19 | 0.732 |
| Renal impairment | 8 | 11 | 0.640 | 6 | 9 | 0.606 |
| Thyroid dysfunction | 12 | 7 | 0.247 | 11 | 7 | 0.344 |
| Focal nodular hyperplasia of the liver | 6 | 1 | 0.067 | 6 | 1 | 0.067 |
| Hepatopathy | 3 | 1 | 0.623 | 3 | 1 | 0.623 |
| Peripheral neuropathy | <1 | 0 | 1.000 | <1 | 0 | 1.000 |
| Growth retardation | 2 | 1 | 1.000 | 2 | 1 | 1.000 |
| Cardiomyopathy | 0 | 2 | 0.230 | 0 | 2 | 0.230 |
| Residual transverse myelopathy | 0 | 1 | 0.481 | 0 | 1 | 0.481 |
| Persisting thrombocytopenia | <1 | 0 | 1.000 | <1 | 0 | 1.000 |
| Visual impairment | 4 | 2 | 0.684 | 3 | 2 | 1.000 |
| Treated as randomised | % of 75 | % of 70 | % of 75 | % of 70 | ||
| Auditory impairment | 33 | 17 | 0.035 | 25 | 14 | 0.145 |
| Renal impairment | 9 | 11 | 0.787 | 7 | 9 | 0.759 |
| Thyroid dysfunction | 13 | 7 | 0.280 | 12 | 7 | 0.404 |
| Focal nodular hyperplasia of the liver | 9 | 1 | 0.064 | 9 | 1 | 0.064 |
| Hepatopathy | 4 | 1 | 0.621 | 4 | 1 | 0.621 |
| Peripheral neuropathy | 1 | 0 | 1.000 | 0 | 0 | n.a |
| Growth retardation | 0 | 1 | 0.483 | 0 | 1 | 0.483 |
| Cardiomyopathy | 0 | 3 | 0.231 | 0 | 3 | 0.231 |
| Residual transverse myelopathy | 0 | 1 | 0.483 | 0 | 1 | 0.483 |
| Persisting thrombocytopenia | 0 | 0 | N.A. | 0 | 0 | N.A. |
| Visual impairment | 3 | 3 | 1.000 | 3 | 3 | 1.000 |
aLate sequelae observed after recurrence of neuroblastoma omitted